InvestorsHub Logo
Followers 230
Posts 21508
Boards Moderated 2
Alias Born 08/03/2006

Re: USAMade post# 2076

Tuesday, 10/29/2019 8:26:57 AM

Tuesday, October 29, 2019 8:26:57 AM

Post# of 3506
News ..."This study highlights an important new finding," commented Walter Klemp, Moleculin's Chairman and CEO. "We've known for some time that Annamycin is effective in AML animal models and the activity that we believe is coming from our current AML clinical trials seems to correlate with this. But, what's new here is the observation that Annamycin may also be more effective than other drugs due to its high uptake and effectiveness in eliminating AML cells localized in different organs. Additional important observations made with these studies indicates that the long-term exposure of healthy mice (at least 12 doses so far) to a highly efficacious dose of 4 mg/kg administered weekly is not toxic and that even two weekly doses of 4 mg/kg are producing a significant increase in survival. And, because Annamycin is designed to be non-cardiotoxic, this extended dosing regimen may prove to be feasible and beneficial in humans. This potentially opens the door for expanded and improved dosing regimens in future clinical trials."



https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/81013294/moleculin-announces-new-data-confirms-anti-tumor-e

"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MBRX News